Inhaled nitric oxide for high-altitude pulmonary edema by Scherrer,  U. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Publisher’s version PDF  
Faculty of Biology and Medicine Publication 
 
 
 “From [Publication Title, Author(s), Title of Article, Volume No., Page No. Copyright © (notice year) 
Massachusetts Medical Society.  Reprinted with permission.
 
Title: Inhaled nitric oxide for high-altitude pulmonary edema. 
Authors: Scherrer U, Vollenweider L, Delabays A, Savcic M, 
Eichenberger U, Kleger GR, Fikrle A, Ballmer PE, Nicod P, Bärtsch P 
Journal: The New England journal of medicine 
Year: 1996 Mar 7 
Volume: 334 
Issue: 10 
Pages: 624-9 
DOI: 10.1056/NEJM199603073341003 
 
 624 THE NEW ENGLAND JOURNAL OF MEDICINE March 7, 1996
 
INHALED NITRIC OXIDE FOR HIGH-ALTITUDE PULMONARY EDEMA
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Abstract
 
Background.
 
Pulmonary hypertension is a
hallmark of high-altitude pulmonary edema and may con-
tribute to its pathogenesis. When administered by inhala-
tion, nitric oxide, an endothelium-derived relaxing factor, at-
tenuates the pulmonary vasoconstriction produced by
short-term hypoxia.
 
Methods.
 
We studied the effects of inhaled nitric oxide
on pulmonary-artery pressure and arterial oxygenation in
18 mountaineers prone to high-altitude pulmonary edema
and 18 mountaineers resistant to this condition in a high-
altitude laboratory (altitude, 4559 m). We also obtained
lung-perfusion scans before and during nitric oxide inhala-
tion to gain further insight into the mechanism of action of
nitric oxide.
 
Results.
 
In the high-altitude laboratory, subjects prone
to high-altitude pulmonary edema had more pronounced
pulmonary hypertension and hypoxemia than subjects re-
sistant to high-altitude pulmonary edema. Arterial oxygen
saturation was inversely related to the severity of pulmo-
nary hypertension (r
 

 
0.50, P
 

 
0.002). In subjects prone
to high-altitude pulmonary edema, the inhalation of nitric
oxide (40 ppm for 15 minutes) produced a decrease in
mean (
 

 
SD) systolic pulmonary-artery pressure that was
three times larger than the decrease in subjects resistant
to such edema (25.9
 

 
8.9 vs. 8.7
 

 
4.8 mm Hg, P
 

 
0.001).
Inhaled nitric oxide improved arterial oxygenation in the
10 subjects who had radiographic evidence of pulmonary
edema (arterial oxygen saturation increased from 67
 

 
10
to 73
 

 
12 percent, P
 

 
0.047), whereas it worsened oxy-
genation in subjects resistant to high-altitude pulmonary
edema. The nitric oxide–induced improvement in arterial
oxygenation in subjects with high-altitude pulmonary ede-
ma was accompanied by a shift in blood ﬂow in the lung
away from edematous segments and toward nonedema-
tous segments.
 
Conclusions.
 
The inhalation of nitric oxide improves ar-
terial oxygenation in high-altitude pulmonary edema, and
this beneﬁcial effect may be related to its favorable action
on the distribution of blood ﬂow in the lungs. A defect in
nitric oxide synthesis may contribute to high-altitude pul-
monary edema. (N Engl J Med 1996;334:624-9.)
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H
 
IGH-ALTITUDE pulmonary edema is a life-threat-
ening condition
 
1
 
 characterized by marked pulmo-
nary vasoconstriction.
 
2-6
 
 Even though the exact under-
lying mechanisms of high-altitude pulmonary edema
are incompletely understood, pulmonary hypertension
is thought to play an important part.
 
3,7-9
 
 On the basis of
the hypothesis that in this condition pulmonary arteri-
olar vasoconstriction is heterogeneous, leading to areas
of hypoperfusion and hyperperfusion, a decrease in pul-
monary-artery pressure may be beneﬁcial in two ways.
A reduction of capillary pressure in overperfused areas
may reduce the formation of edema, whereas augmen-
tation of perfusion in previously underperfused areas,
where gas exchange is not impaired, may improve ox-
ygenation.
When administered by inhalation, nitric oxide, an
endothelium-derived relaxing factor synthesized locally
by the endothelium from the amino acid 
 
L
 
-arginine,
 
10,11
 
attenuates the pulmonary vasoconstriction produced by
short-term hypoxia.
 
12,13
 
 We hypothesized that lowering
pulmonary-artery pressure by administering nitric oxide
may improve oxygenation in persons with high-altitude
pulmonary edema. We therefore studied the effects of in-
haled nitric oxide on pulmonary-artery pressure and ar-
terial oxygenation in mountaineers susceptible to high-
altitude pulmonary edema and those resistant to such
edema after the subjects had ascended rapidly to a high
altitude (4559 m). To gain further insight into the effects
of nitric oxide administration, we performed lung-per-
fusion scans before and during the inhalation of nitric
oxide at high altitude. We also examined the effects of
nitric oxide inhalation on arterial oxygenation during
short-term hypoxia at low altitude.
 
M
 
ETHODS
 
Subjects and Study Design
 
We studied 18 mountaineers (3 women and 15 men; mean [
 

 
SD]
age, 42
 

 
11 years) who had had radiographically documented high-
altitude pulmonary edema within the previous four years. Another 18
mountaineers (5 women and 13 men; mean age, 42
 

 
10 years) with a
history of repeated alpine-style climbing to peaks above 4000 m and no
symptoms of high-altitude pulmonary edema or acute mountain sick-
ness served as controls. One to four weeks after a base-line examination
at 580 m (barometric pressure, 710 mm Hg), the subjects ascended in
groups of two or three from 1130 m to 4559 m (barometric pressure,
440 mm Hg) within a period of 22 hours. The ascent consisted of trans-
port by cable car to an altitude of 3200 m; a 1
 
1
 
⁄
 
2
 
-hour climb to an alti-
tude of 3611 m, where the subjects stayed overnight; and, on the next
morning, a 4
 
1
 
⁄
 
2
 
-hour climb to the high-altitude research laboratory at
Capanna Regina Margherita (Fig. 1). The subjects then spent two days
and two nights at this hut. Two hours after their arrival, each morning
on their two-day stay, and whenever symptoms suggestive of high-alti-
tude pulmonary edema developed, the subjects were examined by the
same observer using the Lake Louise acute mountain sickness scoring
system.
 
14
 
 Brieﬂy, the subject was asked ﬁve questions about the follow-
ing symptoms: headache; gastrointestinal upset; fatigue, weakness, or
both; dizziness, lightheadedness, or both; and difﬁculty sleeping. The
subject was then assessed clinically for three symptoms — namely, a
change in mental status, ataxia, and peripheral edema. The response to
each of the eight items was rated with a 4-point scale in which a score
of 0 indicated no symptoms, 1 mild symptoms, 2 moderate symptoms,
and 3 severe symptoms. The mountain-sickness score is the sum of the
scores for the eight items. The experimental protocol was approved by
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the institutional review board on human investigation, and all subjects
provided written informed consent.
 
Mixing, Administration, and Monitoring of Inspired Gas
 
During the study the subject was supine and wore a face mask con-
nected to a non-rebreathing circuit consisting of a gas-delivery system
with a 30-liter reservoir bag. The inspired gas was room air at high
altitude and a mixture of 10 percent oxygen and 90 percent nitrogen
(to induce hypoxia) at low altitude. Volumetrically calibrated ﬂowme-
ters were used to obtain the desired nitric oxide concentration (40
ppm); nitric oxide mixed with nitrogen at a ﬁxed concentration (1000
ppm of nitric oxide in pure nitrogen) was substituted in a ratio of 0.8
to 19.2 for the inspired gas. Replacement of 4 percent of the inhaled
air with nitric oxide in nitrogen decreased the partial pressure of ox-
ygen by 3.7 and 2.8 mm Hg at high and low altitudes, respectively. At
low altitude, the concentration of nitric oxide in the inspired air was
monitored with a chemiluminescence analyzer (model CLD 700, Eco
Physics, Dürnten, Switzerland).
 
Analysis of Blood Gas and End-Expiratory Gas
 
The fraction of inspired oxygen, minute ventilation, end-tidal oxy-
gen and carbon dioxide concentrations, and hemoglobin oxygen satu-
ration (measured with a pulse oximeter attached to a ﬁngertip) were
recorded continuously (Capnomac Ultima, Datex, Helsinki, Finland).
Before each test this device (which adjusts the measurements auto-
matically in response to changes in atmospheric pressure and temper-
ature) was calibrated with two known gases containing 21 percent ox-
ygen and 0 percent carbon dioxide and 55 percent oxygen and 5.01
percent carbon dioxide, respectively. In a subgroup of 10 subjects
prone to high-altitude pulmonary edema and 13 subjects resistant to
such edema, end-expiratory air and arterialized blood from an ear
lobe were sampled simultaneously. Both samples were analyzed im-
mediately to determine the partial pressures of arterial oxygen and
carbon dioxide (model 278 blood gas system, Ciba–Corning Diag-
nostics, Dietlikon, Switzerland). End-expiratory gas analysis is as-
sumed to provide an estimate of alveolar gas composition. The differ-
ence between the end-expiratory partial pressure of oxygen and the
end-expiratory partial pressure of arterial oxygen is therefore referred
to as the alveolar–arterial oxygen difference.
 
Doppler Echocardiography
 
To measure systolic pulmonary-artery pressure, echocardiographic
recordings were obtained with a real-time, phased-array sector scanner
(model 1500, Hewlett–Packard, Andover, Mass.) with an integrated col-
or Doppler system and a transducer containing crystal sets for imaging
(2.5 MHz) and for continuous-wave Doppler recording (1.9 MHz). The
recordings were stored on VHS videotape for analysis by an investiga-
tor who was unaware of the subject’s clinical history. All reported val-
ues represent the mean of at least three measurements. Systolic pulmo-
nary-artery pressure was calculated from the pressure gradient between
the right ventricle and the right atrium with continuous-wave Doppler
echocardiography and the clinically determined mean jugular venous
pressure.
 
6
 
 Color Doppler echocardiography was used to locate the tri-
cuspid regurgitation jet. The maximal velocity was then determined by
careful application of the continuous-wave sampler on the regurgitation
jet. To calculate the transtricuspid pressure gradient, a modiﬁed Ber-
noulli equation was used, in which transtricuspid pressure equaled four
times the square of the tricuspid-jet velocity. 
Systemic arterial pressure and heart rate were measured with a
Finapres blood-pressure monitor (Ohmeda, Englewood, Colo.).
 
Lung-Perfusion Scintigraphy
 
Lung-perfusion scintigraphy was performed after the intravenous
injection of macroaggregated albumin particles labeled with technetium-
99m (radioactivity, 111 MBq and 444 MBq before and during nitric ox-
ide inhalation, respectively) with a mobile scintillation camera (Trans-
Cam, ADAC, Copenhagen, Denmark) with a divergent collimator and
an acquisition matrix of 256 by 256 pixels. During nitric oxide inha-
lation but before scintigraphy was performed, the residual activity from
the previous scan was determined and then subtracted. For quantitative
analysis, posterior projections were used and each lung was divided into
four contiguous horizontal regions.
 
15
 
 For each region, the average im-
 
Figure 1. The High-Altitude Research Laboratory at Capanna Regina Margherita.
The laboratory is located at the Swiss–Italian border at an altitude of 4559 m.
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pulse rate per pixel was calculated by an investigator who was unaware
of the subject’s history. To assess the effects of nitric oxide inhalation on
lung perfusion, the lung regions for each subject were categorized as
edematous or nonedematous on the basis of radiographic ﬁndings.
 
Radiography
 
On the morning before descent, posteroanterior chest radiographs
were obtained in all subjects with a mobile unit (TRS, Siemens, Stock-
holm, Sweden) with a ﬁxed target-to-ﬁlm distance of 140 cm at 133
kV and 4 to 6 mA · sec
 

 
1
 
. In subjects in whom clinical signs or symp-
toms of high-altitude pulmonary edema developed, additional radio-
graphs were obtained when the symptoms ﬁrst appeared. The radio-
graphs were analyzed according to previously described criteria
 
16
 
 by a
radiologist who was unaware of the subject’s clinical history. Brieﬂy,
with the mediastinum used as the vertical axis and the hila as the hor-
izontal axis, four lung areas were assessed separately for the presence
of edema. Normal parenchyma was given a score of 0; areas with ques-
tionable pathologic ﬁndings, 1; sections in which interstitial disease af-
fected less than 50 percent of the area, 2; sections of nonconﬂuent in-
terstitial disease affecting more than 50 percent of the area, 3; and
areas of alveolar, partly conﬂuent disease, 4. Any radiograph with at
least one lung-quadrant score of 2 or more was considered to be pos-
itive for high-altitude pulmonary edema. To categorize lung-perfusion
scans, each quadrant was subdivided horizontally and the resulting
eight lung regions were assessed separately for the presence of edema.
 
Experimental Protocols
 
Effects of Nitric Oxide Inhalation at High Altitude
 
The subjects were studied in the supine position 18 to 36 hours af-
ter arriving at the hut. They rested quietly for at least 15 minutes be-
fore breathing two gas mixtures sequentially for 12 minutes each:
room air (fraction of inspired oxygen, 0.21), which was used as the
control, and room air supplemented with 40 ppm of nitric oxide (frac-
tion of inspired oxygen, 0.20). In one subject resistant to high-altitude
pulmonary edema it was not possible to administer nitric oxide for
technical reasons. Respiratory responses, oxygenation, systemic arte-
rial pressure, and heart rate were measured continuously, whereas
pulmonary-artery pressure was measured during the last four minutes
of breathing control air or nitric oxide.
 
Effects of Nitric Oxide Inhalation on Lung Perfusion
at High Altitude
 
In four subjects with high-altitude pulmonary edema and two con-
trol subjects, we performed lung-perfusion scintigraphy immediately
before and during the last minute of a 20-minute period of nitric oxide
inhalation at high altitude.
 
Effects of Nitric Oxide Inhalation during Hypoxia
at Low Altitude
 
Eight subjects prone to high-altitude pulmonary edema and six
subjects resistant to this condition participated in this part of the
study. The subjects rested quietly for 15 minutes before breathing
three gas mixtures sequentially for 12 minutes each: a control mixture
with a fraction of inspired oxygen of 0.21, a hypoxic mixture with a
fraction of inspired oxygen of 0.10, and a hypoxic mixture with a frac-
tion of inspired oxygen of 0.096 that contained 40 ppm of nitric oxide.
Respiratory responses and oxygenation were recorded continuously,
whereas pulmonary-artery pressure was measured during the last
four minutes of each of the three periods.
 
Statistical Analysis
 
Statistical analysis ( JMP statistical software, SAS Institute, Cary,
N.C.) was performed with an analysis of variance or the Kruskal–
Wallis test for comparisons between the groups and the two-tailed
t-test or Mann–Whitney rank-sum statistic for single comparisons, as
appropriate. Relations between variables were analyzed by calculat-
ing the Pearson product–moment correlation coefﬁcients. A P value
below 0.05 was considered to indicate statistical signiﬁcance. Unless
otherwise indicated, data are expressed as means 
 

 
SD.
 
R
 
ESULTS
 
After 18 to 36 hours at 4559 m, 10 of the 18 subjects
prone to high-altitude pulmonary edema but none of
the control subjects had radiographic evidence of pul-
monary edema. All 10 of these subjects were studied
while they had radiographic evidence of edema (radio-
graphic score, 2 to 16; mean [
 

 
SD], 9.2
 

 
4.2). In the
control group, symptoms of acute mountain sickness
were absent in 12 subjects and minor in all but 3 (moun-
tain-sickness score, 1 to 9; mean, 3.9
 

 
2.4), whereas most
subjects prone to high-altitude pulmonary edema had
high mountain-sickness scores (range, 3 to 12; mean,
7.5
 

 
2.7; P
 

 
0.001 for the comparison with controls).
Subjects prone to high-altitude pulmonary edema had
more severe hypoxemia than controls and had more pro-
 
*Plus–minus values are means 
 

 
SD. The P values are for the comparisons of changes from base line between study groups. HAPE denotes high-altitude pulmonary
edema, and NS not signiﬁcant.
†Adding nitric oxide to the inhaled gas decreased the fraction of inspired oxygen from 0.21 to 0.20.
‡P
 

 
0.001 for the comparison with changes from base line in subjects resistant to high-altitude pulmonary edema.
§P
 

 
0.005 for the comparison with changes from base line in subjects resistant to high-altitude pulmonary edema.
¶Values are for 13 subjects resistant to high-altitude pulmonary edema, 5 subjects prone to such edema without radiographic evidence of pulmonary edema, and 5 subjects
prone to such edema with radiographic evidence of pulmonary edema.
 

 
P
 

 
0.002 for the comparison with changes from base line in subjects resistant to high-altitude pulmonary edema.
**P
 

 
0.05 for the comparison with changes from base line in subjects resistant to high-altitude pulmonary edema.
††P
 

 
0.04 for the comparison with changes from base line in subjects resistant to high-altitude pulmonary edema.
 
Table 1. Effects of Nitric Oxide Inhalation at High Altitude (4559 m).
 
*
 
V
 
ARIABLE
 
HAPE-R
 
ESISTANT
 
S
 
UBJECTS
 
 (N
 

 
17)
HAPE-P
 
RONE
 
 S
 
UBJECTS
WITHOUT
 
 P
 
ULMONARY
 
 E
 
DEMA
 
 
(N
 

 
8)
HAPE-P
 
RONE
 
 S
 
UBJECTS
WITH
 
 P
 
ULMONARY
 
 E
 
DEMA
 
(N
 

 
10) P V
 
ALUE
BASE
 
 
 
LINE
NITRIC
 
 
 
OXIDE
 
 
 
INHALATION
 
†
 
BASE
 
 
 
LINE
NITRIC
 
 
 
OXIDE
 
 
 
INHALATION
 
†
 
BASE
 
 
 
LINE
NITRIC
 
 
 
OXIDE
 
 
 
INHALATION
 
†
 
Systolic pulmonary-artery
pressure (mm Hg)
43
 

 
7 34
 

 
5 67
 

 
13 42
 

 
6‡ 66
 

 
11 40
 

 
9‡
 

 
0.001
Arterial oxygen saturation (%) 81
 

 
5 79
 

 
5 75
 

 
5 75
 

 
6 67
 

 
10 73
 

 
12§ 0.005
End-tidal carbon dioxide
concentration (mm Hg)
28
 

 
3 29
 

 
6 27
 

 
4 27
 

 
4 28
 

 
2 26
 

 
4 NS
Partial pressure of arterial oxygen 
(mm Hg)¶
46
 

 
5 44
 

 
3 45
 

 
3 43
 

 
4 36
 

 
6 41
 

 
8
 

 
0.003
Alveolar–arterial oxygen
difference (mm Hg)¶
8
 

 
3 7
 

 
3 9
 

 
4 6
 

 
3** 15
 

 
4 11
 

 
3†† 0.04
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nounced pulmonary hypertension (Table 1). There was an
inverse correlation between arterial oxygen saturation and
pulmonary-artery pressure (r
 

 
0.50, P
 

 
0.002) and be-
tween the partial pressure of arterial oxygen and pulmo-
nary-artery pressure (r
 

 
0.48, P
 

 
0.003), whereas the
alveolar–arterial oxygen difference was directly related to
the pulmonary-artery pressure (r
 
0.55, P0.001).
Effects of Nitric Oxide Inhalation at High Altitude
The inhalation of nitric oxide produced a decrease in
pulmonary-artery pressure that was markedly greater
in subjects prone to high-altitude pulmonary edema than
in control subjects (Table 1), and the decrease in pulmo-
nary-artery pressure was directly correlated with the se-
verity of the pulmonary hypertension (r0.89, P0.001).
The decrease in mean systolic pulmonary-artery pres-
sure was 25.98.9 mm Hg in subjects prone to high-
altitude pulmonary edema, as compared with 8.74.8
mm Hg in subjects resistant to such edema. The addi-
tion of nitric oxide to the inhaled air improved arterial
oxygenation in subjects prone to high-altitude pulmo-
nary edema who had pulmonary edema (from 6710 to
7312 percent, P0.047) and did not alter oxygenation
in subjects prone to such edema who did not have ede-
ma, but it consistently impaired oxygenation in subjects
resistant to such edema (Table 1). The changes in arterial
oxygen saturation (r0.40, P0.02), partial pressure
of arterial oxygen (r0.44, P0.04), and the alveolar–
arterial oxygen difference (r0.60, P0.002) were cor-
related with the changes in pulmonary-artery pressure.
The inhalation of nitric oxide did not alter the end-tidal
carbon dioxide concentration (Table 1), minute ventila-
tion, or systemic arterial pressure.
Effects of Nitric Oxide Inhalation on Lung Perfusion at High 
Altitude
In all four subjects prone to high-altitude pulmonary
edema who had pulmonary edema and whom we ex-
amined with lung-perfusion studies, the inhalation of
nitric oxide at high altitude redistributed blood ﬂow in
the lungs away from edematous segments and toward
nonedematous segments (Fig. 2). Before the inhalation
of nitric oxide, the average activity per pixel was higher
in edematous than in nonedematous lung segments
(817 vs. 754 counts per pixel, P0.07) in all four
subjects. The inhalation of nitric oxide increased the
average activity per pixel in the nonedematous lung
segments by a factor of 4 as compared with the edem-
atous lung segments (increase, 123 vs. 33 counts
Before Nitric Oxide Inhalation
A
Before Nitric Oxide Inhalation
B
Maximal
flow
Minimal
flow
During Nitric Oxide Inhalation
C
Figure 2. Effects of Nitric Oxide Inhalation in a Subject with High-
Altitude Pulmonary Edema.
The chest x-ray ﬁlm (Panel A) was obtained a few minutes be-
fore the ﬁrst lung-perfusion scan (Panel B) was obtained. The
second scan (Panel C) was obtained 20 minutes after the start
of nitric oxide inhalation (40 ppm). The inhalation of nitric oxide
redistributed blood ﬂow away from edematous regions of the
lungs and toward nonedematous regions.
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per pixel, P0.009), and in three of
the four subjects the average activity
per pixel became lower in edematous
than in nonedematous lung segments
(848 vs. 886 counts per pixel).
During the inhalation of nitric oxide
the pulmonary blood-ﬂow ratio (the
average activity per pixel of nonedem-
atous lung regions divided by the aver-
age activity per pixel of edematous
lung regions) increased by 136 per-
cent (P0.03). In the two control
subjects studied, the inhalation of ni-
tric oxide did not alter the distribution of blood ﬂow in
the lungs; the average activity per pixel increased similar-
ly and homogeneously in both lungs (by 97 counts per
pixel in the right lung and by 137 counts per pixel in
the left lung).
Effects of Nitric Oxide Inhalation during Hypoxia at Low 
Altitude
The inhalation of a hypoxic gas mixture (fraction of
inspired oxygen, 0.10) decreased arterial oxygen satura-
tion and increased pulmonary-artery pressure to values
that did not differ between the subjects who were prone
to high-altitude pulmonary edema and those who were
not (Table 2). In contrast to the situation at high alti-
tude, lowering of pulmonary-artery pressure by nitric
oxide inhalation did not improve oxygen saturation in
subjects prone to high-altitude pulmonary edema, but
it further decreased arterial oxygen saturation to a val-
ue that was similar to the one observed in subjects who
were resistant to high-altitude pulmonary edema.
DISCUSSION
We found that in subjects with high-altitude pulmo-
nary edema, the inhalation of nitric oxide produced a
large decrease in pulmonary-artery pressure and rapidly
improved arterial oxygenation, even though adding ni-
tric oxide to the inhaled air slightly decreased the frac-
tion of inspired oxygen. In contrast, in subjects resistant
to high-altitude pulmonary edema, adding nitric oxide
to the inhaled gas, although it also reduced the pulmo-
nary-artery pressure, consistently impaired arterial ox-
ygenation. These ﬁndings suggest that in high-altitude
pulmonary edema, but not in high-altitude–induced pul-
monary vasoconstriction alone, the inhalation of ni-
tric oxide exerts beneﬁcial effects on arterial oxygen-
ation.
At high altitude, subjects prone to high-altitude pul-
monary edema had more pronounced pulmonary vaso-
constriction than did subjects resistant to such edema.
During nitric oxide inhalation, however, pulmonary-artery
pressure was similar in both groups because the nitric ox-
ide–induced decrease in pressure was larger in the subjects
prone to edema than in those resistant to edema. These
observations are consistent with the hypothesis that a
defect in nitric oxide–mediated pulmonary vasodilata-
tion — a mechanism that may act as a brake on pulmo-
nary vasoconstriction17 — could contribute to suscepti-
bility to high-altitude pulmonary edema. In line with
this concept, the inhibition of endothelium-dependent
vasodilatation with NG-monomethyl-L-arginine potenti-
ates the pulmonary vasoconstrictor response to short-
term hypoxia in dogs18 and humans.19 Alternatively, it
has also been shown that inhibition of nitric oxide syn-
thesis in cats and rats augments microvascular perme-
ability in several vascular beds.20 Bronchoalveolar lavage
has revealed increased capillary permeability in subjects
with high-altitude pulmonary edema.21 It is possible that
a defect in nitric oxide synthesis could contribute to in-
creased vascular permeability in this condition.
Our results provide some mechanistic insight into ni-
tric oxide–induced effects on pulmonary gas exchange.
In subjects with high-altitude pulmonary edema, the in-
halation of nitric oxide redistributed blood ﬂow in the
lungs away from edematous regions and toward non-
edematous regions, thereby improving the matching
of ventilation and perfusion and reducing the alveolar–
arterial oxygen difference. The more pronounced vaso-
dilatation in nonedematous as compared with edematous
lung regions may be related either to the easier accessi-
bility of nitric oxide to these highly ventilated (and non-
edematous) areas or to augmented vasoconstriction in
these regions, as suggested by the overperfusion hypoth-
esis.7,22 Our ﬁnding of a trend toward high perfusion in
lung regions with radiographic evidence of edema could
be consistent with this latter interpretation. 
In subjects prone to high-altitude pulmonary edema
who had no radiographic evidence of edema, the inha-
lation of nitric oxide decreased the alveolar–arterial ox-
ygen difference (and did not impair arterial oxygen sat-
uration), suggesting that such persons may already have
had clinically relevant ventilation–perfusion mismatch-
es that responded favorably to inhaled nitric oxide. In
contrast, subjects resistant to high-altitude pulmonary
edema did not seem to have relevant mismatches be-
cause the inhalation of nitric oxide did not alter the al-
veolar–arterial oxygen difference and impaired arterial
oxygenation (this effect is attributable to the reduction
of the partial pressure of oxygen by 3.7 mm Hg, caused
by the replacement of 4 percent of the inhaled air by ni-
tric oxide in nitrogen). This interpretation is strength-
ened by the present and previous23 observations of the
effects of nitric oxide inhalation on arterial oxygenation
during short-term hypoxia at low altitude.
A decrease in pulmonary-artery pressure and im-
proved oxygen saturation in subjects with high-altitude
pulmonary edema have also been reported after the
*The fraction of inspired oxygen was 0.10. Plus–minus values are means SD. The P values are for the comparisons
with the base-line values. HAPE denotes high-altitude pulmonary edema, and NS not signiﬁcant.
†Adding nitric oxide to the inhaled gas decreased the fraction of inspired oxygen from 0.10 to 0.096.
Table 2. Effects of Nitric Oxide Inhalation during Hypoxia at Low Altitude.*
VARIABLE HAPE-PRONE SUBJECTS (N  8) HAPE-RESISTANT SUBJECTS (N  6)
BASE LINE
NITRIC OXIDE 
INHALATION† P VALUE BASE LINE
NITRIC OXIDE 
INHALATION† P VALUE
Systolic pulmonary-artery
pressure (mm Hg)
5410 312 0.001 4611 343 0.04
Arterial oxygen saturation (%) 676 627 0.03 677 626 0.03
End-tidal carbon dioxide
concentration (mm Hg)
285 274 NS 274 274 NS
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administration of the vasodilator agents nifedipine,5
hydralazine, and phentolamine.24 In contrast to those
agents, nitric oxide did not alter the systemic arterial
pressure or the heart rate, suggesting that it dilates lung
vessels selectively.13 Although the exact mechanism by
which systemic vasodilators exert their beneﬁcial effects
in high-altitude pulmonary edema needs to be elucidat-
ed, these ﬁndings support the concept that attenuation
of pulmonary vasoconstriction, possibly in conjunction
with a reduction in the ventilation–perfusion mismatch,
plays an important part in both the treatment5,24 and the
prevention6 of high-altitude pulmonary edema.
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